Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Calcium

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,385 result(s) found for: Calcium. Displaying page 11 of 70.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2017-000284-32 Sponsor Protocol Number: SHP634-401 Start Date*: 2018-02-05
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinan...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051315 Congenital hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10075900 Primary hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) DK (Completed) ES (Completed) NO (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001566-90 Sponsor Protocol Number: A6301086 Start Date*: 2008-06-19
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent
    Full Title: A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...
    Medical condition: Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Completed) ES (Completed) NL (Prematurely Ended) CZ (Completed) FR (Completed) AT (Completed) DK (Prematurely Ended) FI (Prematurely Ended) BE (Completed) LT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002806-31 Sponsor Protocol Number: 20120230(KAI-4169-007) Start Date*: 2013-02-12
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease ...
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    14.1 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) SE (Completed) HU (Completed) PL (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000515-95 Sponsor Protocol Number: B3D-EW-GHCX Start Date*: 2005-06-16
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study
    Medical condition: Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015507-52 Sponsor Protocol Number: CLBH589D2308 Start Date*: 2009-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
    Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016492-29 Sponsor Protocol Number: D3561C00002 Start Date*: 2010-03-08
    Sponsor Name:AstraZeneca AB
    Full Title: An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia
    Medical condition: Male and female children and adolescents (aged 6 to < 18 years) with FH* and at least 1 of the following criteria: 1. Fasting LDL-C>190 mg/dL (4.92 mmol/L) at baseline OR 2. Fasting LDL-C >160 ...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003233-41 Sponsor Protocol Number: SVCARB00105 Start Date*: 2005-10-25
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.0 10009122 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001990-53 Sponsor Protocol Number: MK-7902-015(E7080-G000-321) Start Date*: 2020-12-22
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Int...
    Medical condition: Locally advanced unresectable/metastatic gastroesophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10071114 Metastatic gastric adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001378-97 Sponsor Protocol Number: Ped3CB/P01/06/Mu.B Start Date*: 2007-08-14
    Sponsor Name:Baxter SAS
    Full Title: Safety during use of paediatric triple chamber bag formulas administered IV at a weight dependant dose during 5 consecutive days in paediatric patients up to 18 years requiring parenteral nutrition...
    Medical condition: The study is not focussed on a particular pathology but rather on the use of triple chamber bags in paediatrics, in any pathology requiring parenteral nutrition
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051284 Parenteral nutrition PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004643-53 Sponsor Protocol Number: 20050104 Start Date*: 2006-03-14
    Sponsor Name:Amgen Inc.
    Full Title: Bone Histomorphometry Assessment For Incident Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease. Valoración ósea histomorfométrica en pacientes incidentes en diálisis...
    Medical condition: Secondary hyperparathyroidism (HPT) in subjects with CKD receiving dialysis. Hiperparatiroidismo (HPT) secundario en sujetos con IRC tratados con Diálisis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) CZ (Completed) PT (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001280-23 Sponsor Protocol Number: ISO-MTX-003 Start Date*: 2013-09-19
    Sponsor Name:Isofol Medical AB
    Full Title: An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose with Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity d...
    Medical condition: Rescue after High Dose Methotrexate therapy in Osteosarcoma patients.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10061814 Detoxification PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004856-24 Sponsor Protocol Number: AC220-A-U302 Start Date*: 2016-09-02
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 t...
    Medical condition: FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) HU (Completed) ES (Ongoing) RO (Ongoing) BE (Completed) PT (Completed) BG (Completed) HR (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002595-17 Sponsor Protocol Number: CT 06-MEGA-001 Start Date*: 2006-10-25
    Sponsor Name:Recip AB
    Full Title: A randomized, double-blind, parallel-group study evaluating efficacy and safety of MEGA tablets compared to Kalcipos® tablets in adult Subjects
    Medical condition: Vitamin D deficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10047626 Vitamin D deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000539-42 Sponsor Protocol Number: RB2-NL-1518 Start Date*: 2016-04-15
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th...
    Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006692-20 Sponsor Protocol Number: independant Trial (TOMIBA-TRIAL01) Start Date*: 2007-09-06
    Sponsor Name:St. Vincent Hospital, Medical Department II
    Full Title: The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study
    Medical condition: Osteoporosis in Men
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002174-30 Sponsor Protocol Number: B3D-US-GHCV Start Date*: 2005-09-09
    Sponsor Name:Eli Lilly and Company
    Full Title: The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women in Osteoporosis
    Medical condition: Oesteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001022-17 Sponsor Protocol Number: 170304 Start Date*: 2017-05-08
    Sponsor Name:Breastcentre, Capio St Gorans Hospital
    Full Title: Vitamin D supplementation to breast cancer patients with adjuvant endocrine treatment – An observational clinical study where the patient is its own control.
    Medical condition: Breast cancer survivors on adjuvant treatment with an aromatase inhibitor having joint pain
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000526-23 Sponsor Protocol Number: A6181049 Start Date*: 2005-08-30
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Medical condition: Metastatic colorectal cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005310-19 Sponsor Protocol Number: PI-0697-2012 Start Date*: 2013-06-05
    Sponsor Name:FUNDACION PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL_ FPA
    Full Title: Double-blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery
    Medical condition: Children aged 1 month to 14 years in the health area of the province of Granada who will be undergoing heart surgery with a clinical high risk of developing acute heart failure after surgery, treat...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005563-28 Sponsor Protocol Number: EMR 64300-607 Start Date*: Information not available in EudraCT
    Sponsor Name:University Clinic Essen
    Full Title: PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan
    Medical condition: Patients at high risk for CVD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 00:00:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA